BR0312007A - Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas - Google Patents

Controle de taxa de administração transcutânea usando composições farmacêuticas amorfas

Info

Publication number
BR0312007A
BR0312007A BR0312007-4A BR0312007A BR0312007A BR 0312007 A BR0312007 A BR 0312007A BR 0312007 A BR0312007 A BR 0312007A BR 0312007 A BR0312007 A BR 0312007A
Authority
BR
Brazil
Prior art keywords
physiologically active
transcutaneous administration
pharmaceutical compositions
active agent
rate control
Prior art date
Application number
BR0312007-4A
Other languages
English (en)
Other versions
BRPI0312007B1 (pt
Inventor
Timothy Matthias Morgan
Nina Frances Wilkins
Kathryn Traci-Jane Klose
Barrie Charles Finnin
Barry Leonared Reed
Original Assignee
Acrux Dds Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30000668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0312007(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acrux Dds Pty Ltd filed Critical Acrux Dds Pty Ltd
Publication of BR0312007A publication Critical patent/BR0312007A/pt
Publication of BRPI0312007B1 publication Critical patent/BRPI0312007B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"CONTROLE DA TAXA DE ADMINISTRAçãO TRANSCUTâNEA USANDO COMPOSIçõES FARMACêUTICAS AMORFAS". A invenção descreve uma composição farmacêutica para administração transcutânea que compreende um ou mais agentes fisiologicamente ativos; um ou mais intensificadores de penetração cutânea; e um carreador volátil farmaceuticamente aceitável que compreende um solvente volátil; e onde o agente fisiologicamente ativo e o intensificador de penetração cutânea formam um depósito amorfo após evaporação do carreador volátil, o depósito amorfo formando um reservatório dentro da camada córnea; e (A) onde a composição tem um perfil de taxa de liberação de agente fisiologicamente ativo de modo a propiciar uma razão da concentração máxima (C~ max~) para a concentração média (C~ avg~) para o agente fisiologicamente ativo durante o intervalo e dosagem dentro da faixa de 1 a 10.
BRPI0312007-4A 2002-06-25 2003-06-24 Composição farmacêutica para administração transcutânea de testosterona ou fentanil e uso da dita composição BRPI0312007B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39108102P 2002-06-25 2002-06-25
PCT/AU2003/000787 WO2004000263A1 (en) 2002-06-25 2003-06-24 Transdermal delivery rate control using amorphous pharmaceutical compositions

Publications (2)

Publication Number Publication Date
BR0312007A true BR0312007A (pt) 2005-04-12
BRPI0312007B1 BRPI0312007B1 (pt) 2015-04-14

Family

ID=30000668

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0312007-4A BRPI0312007B1 (pt) 2002-06-25 2003-06-24 Composição farmacêutica para administração transcutânea de testosterona ou fentanil e uso da dita composição

Country Status (11)

Country Link
US (4) US8357393B2 (pt)
EP (2) EP1534235B1 (pt)
JP (2) JP5160018B2 (pt)
KR (2) KR20100055542A (pt)
AU (1) AU2003240301B2 (pt)
BR (1) BRPI0312007B1 (pt)
CA (1) CA2489865C (pt)
EA (1) EA009024B1 (pt)
ES (1) ES2589077T3 (pt)
NZ (1) NZ537360A (pt)
WO (1) WO2004000263A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
JP5160018B2 (ja) * 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 非晶質医薬組成物を用いる経皮送達速度調節
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
DE10234673B4 (de) * 2002-07-30 2007-08-16 Schwarz Pharma Ag Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren
US8246980B2 (en) * 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system
US8246979B2 (en) 2002-07-30 2012-08-21 Ucb Pharma Gmbh Transdermal delivery system for the administration of rotigotine
US8211462B2 (en) * 2002-07-30 2012-07-03 Ucb Pharma Gmbh Hot-melt TTS for administering rotigotine
DE60204229T2 (de) * 2002-12-02 2006-02-02 Schwarz Pharma Ag Verabreichung von Rotigotine zur Behandlung der Parkinson'schen Krankheit durch Iontophorese
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
GB0306859D0 (en) * 2003-03-25 2003-04-30 Arachnova Therapeutics Ltd Topical formulation and use of buspirone
GB0319874D0 (en) * 2003-08-22 2003-09-24 Glaxo Group Ltd Novel formulation
US20060263421A1 (en) 2005-05-18 2006-11-23 Abeille Pharmaceuticals Inc Transdermal Method and Patch for Nausea
KR20130114229A (ko) 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물
EP1896038B1 (en) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Method and composition for testosterone transdermal delivery
US20070065494A1 (en) * 2005-08-03 2007-03-22 Watson Laboratories, Inc. Formulations and Methods for Enhancing the Transdermal Penetration of a Drug
KR101608445B1 (ko) 2006-10-12 2016-04-01 비에이치아이 리미티드 파트너쉽 3-아미노-1-프로판설폰산을 전달하기 위한 방법, 화합물, 조성물 및 비히클
BRPI0720945A2 (pt) 2007-01-11 2012-12-25 Acrux Dds Pty Ltd instrumento espalhador
AR068408A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Pulverizacion de hormonas transdermicas
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
MX2010004788A (es) 2007-11-02 2010-09-14 Acrux Dds Pty Ltd Sistema de liberacion transdermica.
KR100929560B1 (ko) * 2008-01-09 2009-12-03 에코 퍼시픽 엘티디 그라니세트론을 함유한 매트릭스 형태의 경피 흡수제
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
KR101292768B1 (ko) * 2010-04-23 2013-08-05 아이큐어 주식회사 경피 흡수 제제
JP5820469B2 (ja) 2010-04-30 2015-11-24 テイコク ファーマ ユーエスエー インコーポレーテッド プロピニルアミノインダンの経皮組成物
PH12013501104A1 (en) * 2010-12-02 2013-07-08 Nexmed Holdings Inc Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate
PL2675453T3 (pl) 2011-02-15 2018-12-31 Elanco Us Inc. Sposoby zwalczania bólu u psów z zastosowaniem przezskórnego roztworu fenantylu
CA2827488C (en) * 2011-02-15 2020-07-07 Audevard Methods for controlling pain in equines using a transdermal solution of fentanyl
CN103476404B (zh) 2011-03-24 2017-09-29 帝国制药美国公司 包含活性剂层和活性剂转化层的透皮组合物
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
AU2013338243B2 (en) 2012-11-02 2016-09-29 Teikoku Seiyaku Co., Ltd. Propynylaminoindan transdermal compositions
US20140271866A1 (en) * 2013-03-15 2014-09-18 Nal Pharmaceuticals, Ltd. Transdermal drug delivery system containing rivastigmine
USD749225S1 (en) 2013-11-26 2016-02-09 Acrux Dds Pty Ltd Topical spreading applicator
USD750788S1 (en) 2013-11-26 2016-03-01 Acrux Dds Pty Ltd Topical spreading applicator
US8785426B1 (en) 2013-12-13 2014-07-22 Upsher-Smith Laboratories, Inc. Testosterone gel compositions and related methods
AU2016235237B2 (en) 2015-03-23 2021-03-11 BioPharmX, Inc. Pharmaceutical tetracycline composition for dermatological use
JP2018177724A (ja) * 2017-04-18 2018-11-15 花王株式会社 外用薬
ES2983874T3 (es) 2018-01-10 2024-10-25 Celista Pharmaceuticals Llc Pulverización transdérmica de testosterona con película
AU2019299538B2 (en) * 2018-07-05 2025-05-08 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (pt) * 1956-03-21 1900-01-01
GB1192003A (en) 1966-05-25 1970-05-13 Struthers Scientific Int Corp Improvements in or relating to Hair Dressing Preparation
GB1258394A (pt) 1968-01-17 1971-12-30
GB1560401A (en) 1976-01-28 1980-02-06 Unilever Ltd Skin treatment composition
DE2920500A1 (de) 1979-05-21 1980-11-27 Boehringer Sohn Ingelheim Pharmazeutische zubereitung in form eines polyacrylatfilmes
US4506803A (en) * 1982-08-09 1985-03-26 Hoffmann-La Roche Inc. Metered aerosol dispenser and method of using the dispenser
DE3311700A1 (de) * 1983-03-30 1984-10-04 Bayer Ag Antimykotische mittel mit hoher wirkstoff-freisetzung in form von loesung und spray
US4912124A (en) * 1984-02-23 1990-03-27 Ortho Pharmaceutical Corporation Antifungal dermatological solution
US5008111A (en) 1984-10-11 1991-04-16 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US4824676A (en) 1984-10-11 1989-04-25 Schering Corporation Physiological means of enhancing transdermal delivery of drugs
US4820724A (en) * 1986-03-31 1989-04-11 University Of Southern California Dual phase solvent carrier system
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US5474783A (en) 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5656286A (en) 1988-03-04 1997-08-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
US5082866A (en) * 1988-06-01 1992-01-21 Odontex, Inc. Biodegradable absorption enhancers
US5164406A (en) 1988-06-02 1992-11-17 Bristol-Myers Squibb Co. Method for enhancing transdermal penetration and compositions useful therein
US5788983A (en) 1989-04-03 1998-08-04 Rutgers, The State University Of New Jersey Transdermal controlled delivery of pharmaceuticals at variable dosage rates and processes
CA2020964A1 (en) 1989-07-12 1991-01-13 Emmett M. Partain, Iii Pharmaceutical active derivative delivery systems
US5091186A (en) 1989-08-15 1992-02-25 Cygnus Therapeutic Systems Biphasic transdermal drug delivery device
JPH0794378B2 (ja) 1989-08-18 1995-10-11 久光製薬株式会社 エアゾール剤
JPH0383924A (ja) 1989-08-28 1991-04-09 Kanebo Ltd 経皮投与用組成物
IL95952A0 (en) * 1989-10-19 1991-07-18 Sterling Drug Inc Aerosol composition for topical medicament
JP3046346B2 (ja) 1990-03-12 2000-05-29 昭和電工株式会社 外用剤基剤又は補助剤とそれを含有する人又は動物の外用剤
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
JP2974081B2 (ja) 1990-07-26 1999-11-08 小池化学株式会社 人体用エアゾール組成物
AU658854B2 (en) 1990-10-18 1995-05-04 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
US5122383A (en) 1991-05-17 1992-06-16 Theratech, Inc. Sorbitan esters as skin permeation enhancers
DK0617612T3 (da) * 1991-12-18 1998-04-14 Warner Lambert Co Fremgangsmåde til fremstilling af en fast dispersion
EP0560014A1 (en) 1992-03-12 1993-09-15 Atrix Laboratories, Inc. Biodegradable film dressing and method for its formation
JPH08501529A (ja) 1992-06-11 1996-02-20 セラテック・インコーポレイテッド 皮膚透過薬剤投与緩和のグリセリン使用
EP0581587A3 (en) 1992-07-31 1995-05-17 Tanabe Seiyaku Co Base material for transdermal administration.
DE4230588C1 (de) 1992-09-12 1993-10-07 Lohmann Therapie Syst Lts Dexpanthenol-haltiges Pflaster zur transdermalen Applikation von Steroidhormonen und Verfahren zu seiner Herstellung
US5613958A (en) 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
DE4334553C2 (de) * 1993-10-11 1998-05-20 Synopharm Gmbh Pharmazeutische Flüssiges pharmazeutisches System zur perkutanen Applikation
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6416760B2 (en) * 1995-01-26 2002-07-09 Societe L'oreal Therapeutic/cosmetic compositions comprising CGRP antagonists for treating sensitive human skin
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
FR2732223B1 (fr) 1995-03-30 1997-06-13 Sanofi Sa Composition pharmaceutique pour administration transdermique
US5780050A (en) 1995-07-20 1998-07-14 Theratech, Inc. Drug delivery compositions for improved stability of steroids
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
US6916487B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6998138B2 (en) * 1996-02-19 2006-02-14 Acrux Dds Pty. Ltd. Topical delivery of anti-alopecia agents
US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
US6004969A (en) * 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
DE19616539A1 (de) * 1996-04-25 1997-11-06 Luitpold Pharma Gmbh Acetylsalicylsäure enthaltende alkoholische Lösungen zur perkutanen Anwendung, deren Verwendung zur antithrombotischen Therapie sowie Arzneimittel
US6638948B1 (en) 1996-09-09 2003-10-28 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
AUPO379596A0 (en) * 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
DE19701949A1 (de) 1997-01-13 1998-07-16 Jenapharm Gmbh Transdermales therapeutisches System
IT1294748B1 (it) * 1997-09-17 1999-04-12 Permatec Tech Ag Formulazione per un dispositivo transdermico
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin
DK1510213T3 (da) 1997-11-10 2009-03-23 Strakan Int Ltd Penetrationsforbedrende og irritationsreducerende systemer omfattende testosteron
EP0919550A1 (en) * 1997-11-26 1999-06-02 Ucb, S.A. Pseudopolymorphic forms of 2-2-4-bis(4-fluorophenyl)methyl-1-piperazinyl-ethoxy acetic acid dihydrochloride
EP1102579B1 (de) * 1998-08-04 2003-03-19 Jago Research Ag Medizinische aerosolformulierungen
US5962505A (en) * 1998-08-31 1999-10-05 Bobrove; Arthur M. Method for treating hot flashes in humans
DE19843027A1 (de) * 1998-09-19 2000-03-23 Labtec Gmbh Neohesperidin DC als Kristallisationsinhibitor
US6663874B2 (en) * 1998-11-02 2003-12-16 Victor Stevens Composition to alleviate pain and topical method of applying same
DK1150661T3 (da) * 1999-02-05 2004-03-01 Cipla Ltd Topiske sprays der omfatter et filmdannende præparat
DE19906152B4 (de) 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
US6399093B1 (en) * 1999-05-19 2002-06-04 Advanced Medical Instruments Method and composition to treat musculoskeletal disorders
JP2001270826A (ja) 1999-09-28 2001-10-02 Shoei:Kk 皮膚疾患治療・予防用外用剤
EP1231877A4 (en) * 1999-11-04 2009-03-18 Xel Herbaceuticals TRANSDERMALE ADMINISTRATION OF HUPERZIN
AU4515001A (en) * 1999-12-02 2001-06-18 Regents Of The University Of Michigan, The Compositions and methods for locally treating inflammatory diseases
US6432415B1 (en) * 1999-12-17 2002-08-13 Axrix Laboratories, Inc. Pharmaceutical gel and aerosol formulations and methods to administer the same to skin and mucosal surfaces
JP2004159666A (ja) * 1999-12-21 2004-06-10 Ya Man Ltd レーザ脱毛器
IN191512B (pt) * 2000-01-21 2003-12-06 Panacea Biotech
US6562790B2 (en) 2000-02-05 2003-05-13 Chein Edmund Y M Hormone therapy methods and hormone products for abating coronary artery blockage
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
WO2005039531A1 (en) 2003-10-10 2005-05-06 Antares Pharma Ipl Ag Transdermal pharmaceutical formulation for minimizing skin residues
IN191090B (pt) * 2000-08-29 2003-09-20 Ranbanx Lab Ltd
US20030139384A1 (en) 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
IL154693A0 (en) 2000-08-30 2003-09-17 Unimed Pharmaceuticals Inc Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2001286995B2 (en) 2000-08-30 2006-11-30 Besins Healthcare Luxembourg Sarl Method for treating erectile dysfunction and increasing libido in men
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
GB0029634D0 (en) * 2000-12-05 2001-01-17 Norway Medical Group Int As Use
US6743448B2 (en) 2000-12-11 2004-06-01 Abraham H. Kryger Topical testosterone formulations and associated methods
US20050084553A1 (en) 2002-01-26 2005-04-21 Woong-Sig Moon Composition containing moutan root bark extract as active ingredient
US20030199584A1 (en) 2002-04-11 2003-10-23 Ahluwalia Gurpreet S. Reduction of hair growth
AUPS317102A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
JP5160018B2 (ja) * 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 非晶質医薬組成物を用いる経皮送達速度調節
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
US8206696B2 (en) 2002-12-30 2012-06-26 Aplicare, Inc. Antimicrobial skin preparation
GB0302662D0 (en) 2003-02-05 2003-03-12 Strakan Ltd Transdermal granisetron
FR2851470B1 (fr) 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
US20050020552A1 (en) * 2003-07-16 2005-01-27 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050042268A1 (en) 2003-07-16 2005-02-24 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
US20050025833A1 (en) 2003-07-16 2005-02-03 Chaim Aschkenasy Pharmaceutical composition and method for transdermal drug delivery
MXPA06005743A (es) * 2003-11-19 2007-04-17 Acrux Dds Pty Ltd Metodo y composicion para el tratamiento o profilaxis de trastornos de amiloidosis.
US20050123576A1 (en) 2003-12-03 2005-06-09 Ilana Lavon Mupirocin compositions for topical use, an improved process of making same and methods of using same
CA2558408C (en) 2004-03-03 2014-11-18 Essentia Biosystems, Inc. Compositions and methods for topical application and transdermal delivery of botulinum toxins
EP1634583A1 (en) 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
KR20130114229A (ko) * 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물

Also Published As

Publication number Publication date
ES2589077T3 (es) 2016-11-10
US20100166674A1 (en) 2010-07-01
EP1534235B1 (en) 2016-07-27
EA009024B1 (ru) 2007-10-26
KR20100055542A (ko) 2010-05-26
BRPI0312007B1 (pt) 2015-04-14
EP1534235A4 (en) 2008-06-18
US20150094290A1 (en) 2015-04-02
HK1077192A1 (en) 2006-02-10
EA200500084A1 (ru) 2005-06-30
EP1534235A1 (en) 2005-06-01
EP2266533A2 (en) 2010-12-29
AU2003240301A1 (en) 2004-01-06
AU2003240301B2 (en) 2008-02-14
JP2006501172A (ja) 2006-01-12
EP2266533A3 (en) 2011-12-14
CA2489865C (en) 2012-05-08
US8784878B2 (en) 2014-07-22
US8357393B2 (en) 2013-01-22
NZ537360A (en) 2006-09-29
CA2489865A1 (en) 2003-12-31
US20130316996A1 (en) 2013-11-28
JP5568108B2 (ja) 2014-08-06
KR20050045946A (ko) 2005-05-17
JP5160018B2 (ja) 2013-03-13
JP2012162557A (ja) 2012-08-30
WO2004000263A1 (en) 2003-12-31
US20050175680A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
EA200500084A1 (ru) Фармацевтическая композиция для чрескожной доставки активного агента
ES2880624T3 (es) Preparaciones tópicas de vasoconstrictores y métodos para proteger células durante quimioterapia y radioterapia contra el cáncer
DK1311249T3 (da) Sæt af transdermale terapeutiske systemer
BR0016012A (pt) Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração
ATE493981T1 (de) Einmal tägliche dosierformen von trospium
ATE544447T1 (de) Arzneistoffcoating mit hohem wirkstoffanteil sowie methoden zu dessen herstellung
CY1109861T1 (el) Διαδερμικο θεραπευτικο συστημα για την ασθενεια του παρκινσον που προκαλει υψηλα επιπεδα πλασματος της ροτιγοτινης
DK1256343T3 (da) Flibanserin til behandlingen af extrapyramidale bevægelseslidelser
KR20180088415A (ko) 국소적 막형성 스프레이
BR0318319A (pt) métodos de preparação e formulações/composições sustentadas pelo uso de dimeticona como veìculo
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease
CO5130022A1 (es) Sistema de entrega controlado de droga administrado oralmente, que provee control temporal y espacial
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
SG146638A1 (en) Pharmaceutical delivery system
DE60211139D1 (de) Feste arzneizusammensetzung enthaltend 4'-cyano-trifluoro-3-(4-fluorophenylsulphonyl) -2-hydroxy-2-methylpropiono- m toluidide und pvp
AU9551201A (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic diseasestates
AR046146A1 (es) Formulaciones farmaceuticas transdermicas para pulverizacion que comprenden un agente activo, un copolimero de vp/va y un vehiculo no acuoso
BR0312004A (pt) Composições de aerossol transdérmicas
BR0316770A (pt) Formulação farmacêutica, método de produção da mesma e método de tratamento médico
EA200400348A1 (ru) Цисплатиновые составы пониженной токсичности и способы их применения
JP2004203824A (ja) 鼻腔用組成物及びその使用方法
BR0208475A (pt) Solução para administração intravenosa, e, método para a produção de uma solução de amiodarona adequada para administração intravenosa
BR0312003A (pt) Composições farmacêuticas metaestáveis para distribuição transdérmica e seus usos
JP2017226618A (ja) リュープロレリンの経皮吸収型製剤
JP2014122167A (ja) 眼科用組成物

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 9/00, A61K 9/12, A61K 9/70, A61P 25/22

Ipc: A61K 9/00 (2011.01), A61K 9/06 (2011.01), A61K 9/1

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 14/04/2015, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2519 DE 16-04-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.